Arrhythmias & electrophysiology
Linear accelerator–based stereotactic arrhythmia radioablation for paroxysmal atrial fibrillation in elderly: a prospective phase II trial
Authors' conclusion
The present phase II trial demonstrated the feasibility of STAR in paroxysmal AF elderly patients and its potential role in increasing the quality of life.
Study context
- Population
- Elderly patients (>70 years) with symptomatic paroxysmal atrial fibrillation (AF) and antiarrhythmic drug failure or intolerance18 underwent stereotactic arrhythmia radioablation (STAR)
- Participants
- 20 patients
- Outcome
- Feasibility of STAR
Methodological detailssingle-arm
- Single-arm
Main finding
As reported in the abstract
Feasibility · median follow-up 16 months (range 12-23)
- No acute toxicity more than Grade 3
- Most patients had a significant reduction in AF episodes
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Recurrence with electrophysiological study documenting successful PV isolation | STAR Five events |
Quality of life · 12 months
- Enrolment vs 12 months: 48 ± 15 vs 75 ± 15
- P < 0.001
Safety
| Outcome | Values |
|---|---|
| Adverse events | STAR Grade 1 oesophagitis 24 h after STAR Five · Asymptomatic Grade 1 pericardial effusion eight · Torsade de pointes (treated by cardioversion and ICD implantation) one |
Original publication
Linear accelerator–based stereotactic arrhythmia radioablation for paroxysmal atrial fibrillation in elderly: a prospective phase II trial. Europace. Published 21 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →